BRIEF published on 04/03/2025 at 13:24, 7 days 17 hours ago Innate Pharma participates in the Stifel 2025 Virtual Targeted Oncology Forum Euronext Paris Oncology Immunotherapy Innate Pharma Virtual Forum
BRIEF published on 04/03/2025 at 13:18, 7 days 17 hours ago Innate Pharma to Engage in Stifel 2025 Virtual Oncology Forum Biotechnology Immunotherapy Virtual Event Innate Pharma Oncology Forum 2025
PRESS RELEASE published on 04/03/2025 at 13:13, 7 days 17 hours ago INSIDE INFORMATION / OTHER NEWS RELEASES Innate Pharma to participate in 2025 Stifel Virtual Targeted Oncology Forum. Executive team presenting and hosting 1x1 meetings. Focus on innovative cancer immunotherapies Cancer Innate Pharma Immunothérapies Stifel Targeted Oncology Forum
PRESS RELEASE published on 03/28/2025 at 14:37, 13 days 15 hours ago Annual financial and audit reports / Annual financial report
BRIEF published on 03/20/2025 at 07:05, 21 days 23 hours ago Innate Pharma Announces 2024 Financial Results Conference Financial Results Conference Call Stock Market Listing Cancer Immunotherapy Innate Pharma
PRESS RELEASE published on 03/20/2025 at 07:00, 21 days 23 hours ago Inside Information / Other news releases Innate Pharma to hold conference call and webcast for full year 2024 financial results on March 27, 2025. Details for participation provided Financial Results Conference Call Biotechnology Webcast Innate Pharma
BRIEF published on 02/17/2025 at 07:07, 1 month 21 days ago Innate Pharma Receives Breakthrough Therapy Designation from FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Sézary Syndrome
PRESS RELEASE published on 02/17/2025 at 07:02, 1 month 21 days ago Inside Information / Other news releases Innate Pharma receives U.S. FDA Breakthrough Therapy Designation for Lacutamab in Sézary syndrome treatment, showing promising results in Phase 2 TELLOMAK study FDA Innate Pharma Lacutamab Sézary Syndrome Breakthrough Therapy Designation
BRIEF published on 01/27/2025 at 07:05, 2 months 14 days ago Innate Pharma Initiates Phase 1 Study of IPH4502 for Advanced Solid Tumors Phase 1 Trial Innate Pharma IPH4502 Nectin-4 Advanced Solid Tumors
PRESS RELEASE published on 01/27/2025 at 07:00, 2 months 14 days ago Inside Information / Other news releases Innate Pharma announces first patient dosed in Phase 1 study of Nectin-4 targeting Antibody Drug IPH4502 in advanced solid tumors. Innovative ADC for multiple cancer types Innate Pharma Phase 1 Study IPH4502 Topoisomerase I Inhibitor Antibody Drug Conjugate
Published on 04/11/2025 at 02:40, 3 hours 50 minutes ago McFarlane Lake Announces Closing of Final Tranche of Upsized $1.3 Million Private Placement Offering
Published on 04/11/2025 at 02:00, 4 hours 30 minutes ago Battery X Metals Announces Formation of Critical Battery Metals Exploration Subsidiary and Expansion of Quebec Exploration Portfolio with Acquisition of 39 Additional Mineral Claims
Published on 04/11/2025 at 00:00, 6 hours 30 minutes ago Onco-Innovations’ Inka Health Publishes Roche-Sponsored Study Advancing Real-World Oncology Research
Published on 04/10/2025 at 23:00, 7 hours 30 minutes ago Highlander Silver Receives Conditional Approval to List on the TSX, Files Base Shelf Prospectus and Establishes ATM Program as Longer Term Financial Alternatives
Published on 04/11/2025 at 06:00, 30 minutes ago Sales for the first quarter 2025 Ad hoc announcement pursuant to Art. 53 LR
Published on 04/11/2025 at 05:00, 1 hour 30 minutes ago LISA with Leading Thai and International Artists Captivate the World at the Amazing Thailand Countdown 2025, Reinforcing ICONSIAM as the Ultimate Global Countdown Destination
Published on 04/10/2025 at 20:47, 9 hours 43 minutes ago EQS-Adhoc: Hinkel & Cie. GmbH: first creditors´meeting of the bond DE000A2AAPX4
Published on 04/10/2025 at 20:44, 9 hours 46 minutes ago EQS-Adhoc: artnet AG: artnet is in talks with two investors regarding a potential takeover offer
Published on 04/10/2025 at 19:00, 11 hours 30 minutes ago Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Published on 04/10/2025 at 17:45, 12 hours 45 minutes ago EURAZEO INVESTS IN EKOSCAN INTEGRITY, A LEADING GLOBAL PROVIDER OF ADVANCED NON-DESTRUCTIVE TESTING SOLUTIONS FOR CRITICAL INDUSTRIAL APPLICATIONS AND INFRASTRUCTURE
Published on 04/09/2025 at 18:59, 1 day 11 hours ago Description of the 2025-2026 Share Buyback Program
Published on 04/09/2025 at 18:57, 1 day 11 hours ago Minutes of the Combined General Meeting held on April 9, 2025
Published on 04/09/2025 at 17:45, 1 day 12 hours ago COGELEC : 2024 full-year results and Q1 2025 revenue.
